New drug combo shows promise for myeloma patients ineligible for transplant
NCT ID NCT03984097
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 1b trial tested the safety of adding TAK-079 (Mezagitamab) to standard treatments for 50 people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. The goal was to find the right dose and watch for side effects. Researchers also tracked how well the cancer responded to treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TAK-079 (also called Mezagitamab) combined with lenalidomide, dexamethasone, bortezomib, or pomalidomide
What this could lead to
If successful, this could help determine a safe dose of TAK-079 for treating multiple myeloma, potentially improving disease control when used with standard therapies.
What could go wrong
This is an early-phase trial with only 50 participants, so results may not apply to all patients. Side effects from the drug combination are possible, and the study focuses on safety, not effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alabama Oncology
Birmingham, Alabama, 35211, United States
-
American Oncology Partners of Maryland, PA
Bethesda, Maryland, 20817, United States
-
Columbia University Medical Center
New York, New York, 10032, United States
-
Froedtert Hospital & the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Good Samaritan Hospital
Cincinnati, Ohio, 45220, United States
-
Levine Cancer Institute
Charlotte, North Carolina, 28204, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Oregon Health & Science University
Portland, Oregon, 97239, United States
-
Pacific Cancer Care
Monterey, California, 93940, United States